Patient-led Translational Work
TMJ Patient RoundTable

Deanne Clare, Association Administrator
The TMJ Association, Milwaukee, WI
There is an urgent need to understand factors that lead to success or failure for all TMD treatments.

The current state of TMD treatment is supported by sparse evidence on the safety and effectiveness.

Trial-and-error is the typical approach in treating TMD patients and the outcomes of this approach are less than satisfactory.
TMJ RoundTable Steering Committee

Co-Chairs:
- **Terrie Cowley**, President & Co-Founder, The TMJ Association, WI
  - **Danica Marinac-Dabic, MD, PhD, MMSc**, Director, Division of Epidemiology, CDRH/FDA

Members:
- **Elise Berliner, PhD**, Director, Technology Assessment Program at the Center for Outcomes and Evidence in the Agency for Healthcare Research and Quality, MD
- **Telba Irony, PhD**, Deputy Director, Office of Biostatistics and Epidemiology, CBER/FDA
- **Peter Quinn, MD**, Vice Dean, University Of Pennsylvania Medical School, Philadelphia, PA
- **Joseph Ross, MD, MHS**, Yale School of Medicine, Associate Professor of Medicine (General Medicine) and in the Institute for Social and Policy Studies and Associate Professor of Public Health, New Haven, CT
- **Susan Runner, DDS, MA**, Branch Chief Dental Devices, CDRH/FDA/ODE
- **Dave Samson**, President, TMJ Concepts, CA
- **Art Sedrakyan, MD, PhD**, Associate Professor of Healthcare Policy and Research and Director of the Comparative Effectiveness Program of Weill Cornell Medical College, NY
- **Martha Somerman, PhD, DDS**, Director, NIDCR/NIH
- **Yelizaveta Torosyan, MD, PhD**, Acting Senior Project Manager, Division of Epidemiology, CDRH/FDA

Project Managers/Liaisons:
- **Deanne Clare**, Association Administrator, The TMJ Association, WI
- **Marta Steliac**, Health Science Administrator, Division of Epidemiology, CDRH/FDA, MDEpiNet Project Manager
Working Group 1

The TMJ Patient: Natural History and Assessment of Biomarkers Associated with Outcomes in TMJ Implant Patients

Co-Chairs:

• John Kusiak, PhD, Acting Deputy Director, NIDCR/NIH

• Christin Veasley, Co-Founder and Executive Director, Chronic Pain Research Alliance, RI
Working Group 2

Patient-Reported Outcome Evaluation & Real-World Evidence & Patient Data

Co-Chairs:

• Joel Gagnier, ND, MSc, PhD, Assistant Professor, Department of Orthopaedic Surgery, Assistant Professor, Department of Epidemiology, School of Public Health, University of Michigan, MI

• Carolina Alvarez-Garriga, MD, DrPH, Epidemiologist, Epidemiology, OSB/CDRH/FDA

• Tricia Kalinowski, TMJ Patient, MN

• Michele Kaseta, TMJ Patient, MI
Working Group 3

Education, Patient-Centered Treatment

Co-Chairs:

• Charles Greene, DDS, Clinical Professor of Orthodontics, University of Illinois at Chicago, IL
• Michelle Reardon, TMJ Patient Rep., MA
Expected Project Outcomes

• Patient-preferences will be included in premarket applications and post-market surveillance efforts for all TMD treatments.

• Provide a roadmap for the development of precision medicine algorithms that predict individual outcomes from TMJ therapies.

• Evidence-based protocols, guidelines and best practices will be developed and included in professional health care curriculum.

• Collaborative and individual research projects will incorporate the needs and concerns of patients.
Thank you